Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study
Abstract
Background: Chemoresistance is a major challenge in ovarian cancer treatment, resulting in poor survival rates. Identifying markers of treatment response is imperative for improving outcome while minimizing unnecessary side effects. We have previously demonstrated that expression of transducin-like enhancer of split 3 (TLE3) is associated with favorable progression-free survival in taxane-treated ovarian cancer patients with nonserous histology. The purpose of this study was to perform an independent evaluation of the association of TLE3 expression with response to taxane-based chemotherapy in nonserous ovarian cancer, to validate its role as a potential therapeutic response marker for taxane-based chemotherapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 31, 2018
- Source ID
- 10.1158/1055-9965.epi-17-1101
Entities
People
- Alison Brand
- Anna deFazio
- Brian Z. Ring
- Catherine J Kennedy
- David D.l. Bowtell
- Goli Samimi
- Nadia Traficante
- Paul Harnett
- Raghwa Sharma
- Rajmohan Murali
- Robert A. Soslow
- Sian Fereday
Organizations
- Cancer Institute of New South Wales
- Huazhong University of Science and Technology
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Health and Medical Research Council
- United States Army Medical Research and Development Command
- Western Sydney University
- Westmead Hospital
- Westmead Institute for Medical Research